Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

FDA issued a complete response letter for Mylan's application for a biosimilar version of Amgen's Neulasta. However, Mylan said the CRL does not change its US launch expectations, targeted for late 2018 or early 2019.

Mylan NV is the fourth company to receive a complete response letter from FDA related to a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim), highlighting the challenges with bringing a copy of the pegylated neutropenia drug to market.

Mylan and its biosimilar development partner Biocon Ltd. announced the CRL Oct. 10 and said it was related to a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics